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Chapter
Epstein-Barr Virus: Should We 




The complex interplay between host and EBV has made it difficult to elaborate 
useful vaccines protecting against EBV diseases. It is encouraging to see that EBV 
vaccine programs have started to incorporate different arms of the immune system. 
An array of argument calls for a realistic goal for vaccine strategies which should be 
preventing EBV diseases, rather than EBV infection. EBV is the primary cause of 
infectious mononucleosis and is associated with epithelial cell carcinomas, as well 
as lymphoid malignancies. Parallel to this need, one could propose priorities for 
future research: (i) identification of surrogate predictive markers for the develop-
ment of EBV diseases (ii) determination of immune correlates of protection in 
animal models and humans.
Keywords: vaccine, early diagnosis, lymphomas, EBV diseases
1. Introduction
More than 95% of the world’s adult population is infected with the Epstein–Barr 
Virus (EBV or HHV4), a virus belonging to the Herpesviridae family that mainly 
infects B lymphocytes. Human Herpesviruses (HHV1–8) have co-evolved through 
persistent infections in their hosts which are spread efficiently to others and gener-
ally do not cause serious disease (Table 1) [1]. EBV is transmitted by saliva, usually 
infects its host during infancy and is largely asymptomatic. If the infection does 
occur later, in adolescence or young adulthood, in about 40% of cases it leads to the 
development of an acute condition called infectious mononucleosis (IM). In the 
United States alone, 125,000 cases of IM are reported each year. EBV is also associ-
ated with the development of several malignancies derived either from lymphocytes 
or from epithelial cells (Table 1). It is estimated that about 10% of cancers associ-
ated with a viral infection are associated with EBV and that each year, on average, 
about 200,000 new cases of EBV-associated cancers are diagnosed worldwide [2]. 
Furthermore, EBV is also associated with the development of autoimmune diseases 
such as multiple sclerosis [3]. The complex interplay between the Herpesviruses 
and their hosts has made it difficult to elaborate useful vaccine strategies to protect 
against HHV-associated diseases [4]. Over the years, the development of HHV 
vaccines has been a story of mixed fortunes, especially for HSV-2 and HCMV 
(Table 2). The frequent presence of EBV in many pathologies is an indicator of the 
necessity of developing a vaccine against EBV. The argument was first put forward 
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more than 40 years ago by Sir Antony Epstein, the pathologist and expert electron 
microscopist who discovered the EBV virus [5]. However, to date, despite sustained 
efforts, the EBV vaccine has not been finalized, even though promising results have 
been obtained [6, 7]. The main difficulty in developing an anti-EBV vaccine stems 
from the patchy nature of our knowledge of the course of EBV infection in vivo.
Below we review the history of the EBV vaccine development, and current 
strategies involved. At the same time, one could propose priorities in terms of 
future research, such as (i) a better definition of the goal for an EBV vaccine; and 
(ii) the identification of costless surrogate markers that predict the development of 
EBV-related malignancies.
2.  The first challenge for EBV vaccines: the complexity of the biological 
cycle of EBV
The EBV lifecycle is considerably complex and passes through a phase of 
latent infection during which the virus induces the activation, proliferation, and 
differentiation of primary B cells into memory B cells [8, 9]. During this phase, 
the infection elicits a humoral and cellular immune response directed against the 
proteins of the latent phase. During the terminal differentiation into plasma cells 
of infected cells, the productive viral cycle is activated and virions are produced 
which will be able to infect epithelial cells capable of producing a large number of 
viral particles. The numerous viral proteins expressed during the production cycle 





Common name Common manifestations Antiviral 
therapy
Alpha- HSV-1 Herpes Simplex Virus 
type 1
Cold sores, keratitis, 
encephalitis
+++
Alpha- HSV-2 Herpes Simplex Virus 
type 2
Genital sores +++
Alpha- VZV Varicella Zoster Virus Chicken pox, shingles +++
Beta- HCMV Human 
Cytomegalovirus




Beta- HHV-6 Human 
Herpesvirus-6
Roseola infantum, rash 
& fever
—
Beta- HHV-7 Human 
Herpesvirus-7
Roseola infantum, rash 
& fever
—
Gamma- EBV Epstein-Barr Virus Infectious mononucleosis, 
lymphoid malignancies, 
nasopharyngeal & gastric 
carcinoma
+/−
Gamma- HHV-8 Human 
Herpesvirus-8
Kaposi sarcoma —
+++ widely used and successful, ++ widely used and quite successful, + occasionally used with limited success, − 
rarely used with an uncertain outcome.
Table 1. 
List of the major herpesviruses pathogenic for humans. First the alpha- including neurotropic viruses, second 
the beta- with the most salient virus, CMV. This virus infects a large number of cells and is responsible for a lot 
of serious diseases in the immunocompromised hosts. HHV6 and HHV7 are lymphotropic viruses, responsible 
of roseola, and rash and fever in adults. Finally, the gamma- which includes B lymphotropic viruses with 
transforming activities.
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Herpesvirus Site of latency and persistence Pathology Vaccine trials Antivirals Prevalence Transmission
HHV1 (HSV1) Neurons (sensory ganglia) Widespread vesicular lesions and 
neurological diseases
No ongoing vaccine 
research
YES High Skin contact
HHV2 (HSV2) Neurons (sensory ganglia) One of the most prevalent sexually 
transmitted infections worldwide




HHV3 (VZV) Neurons (sensory ganglia) Chickenpox Live vaccine available YES High Respiratory tract
HHV4 (EBV) B Lymphocytes (oropharyngeal 
epithelium)
IM, lymphoid & epithelial tumors In clinical trials no 
regulatory-approved 
vaccines
YES Very high Saliva
HHV5 (CMV) Blood monocytes /bone marrow 
precursors (probably epithelial 
cells)
Significant disease in pregnancy and 
immunocompromised patients
In clinical trials no 
regulatory-approved 
vaccines
YES High Sexual, blood, 
saliva, urine
HHV6 Monocytes, T lymphocytes Roseola infantum — Not 
relevant
HHV7 Monocytes, T lymphocytes Roseola infantum — Not 
relevant






Main features of the HHVs. Some vaccines exist, for example the Varilrix© and Zostavax© against VZV. Clinical studies about some other vaccines are in progress (CMV and EBV).
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Vaccine candidates EBV antigens used Results
Epitope vaccine EBNA3A Induced EBNA3A-specific T-cell responses
Did not protect against EBV infection. Lower incidence 





Targeting of DC enabled the induction of EBNA-
1spcefic CD4+ and CD8+ T cells
Vaccination of humanized mice generated EBNA1 
specific T cells
Monomeric gp350 Induced neutralizing gp350-specific antibodies.
Reduced incidence of IM
Did not protect against EBV infection.
Multimeric Tetrameric gp350
Trimeric gH/gL and 
trimeric gB
Higher immunity (neutralizing antibodies) of 
tetrameric gp350 compared to that of monomeric one 
(vaccinated rabbits).
Higher immunity (neutralizing antibodies) of trimeric 
gH/gL and trimeric gB compared to that of monomeric 
gp350 (vaccinated rabbits).
Nanoparticles gp350 Higher immunity (neutralizing antibodies) of 
gp350-containing nanoparticles, compared to that of 




gH/gL, gp42, LMP2 & 
EBNA1
Higher immunity (neutralizing antibodies) of gp350-
containing NDV*-VLPs, compared to that of monomeric 
gp350 (vaccinated mice).
Use of NDV*-VLP platform to combine EBV lytic and 
latent antigens
EBV VLPs More than three dozen 
structural proteins
More than three dozen 
structural proteins & 
EBNA1
Similar antigenicity with wt EBV












Antibody titers against viral proteins involved in 
epithelial cell entry (gH/gLand gB) or B cell entry 
(gp350, gH/gLand gB) were measured in peripheral 
blood at day 57 (mice)
Table 3. 
Summary of prophylactic EBV vaccine candidates that have been developed (from ref. [7]) * NDV Newcastle 
disease.
approximately 80 proteins, 15 of which possess at least 90 antigenic epitopes. A 
large quantity of these proteins stimulates the T-cell receptors (TCRs), but a few 
interact with the B-cell receptors (BCRs) [11]. Activation of B cells and subsequent 
antibody production has not only been related to at least 3 envelope glycoproteins 
(mostly gp350) but also to latency-associated membrane proteins (LMPs). The 
majority of EBV epitopes inducing either cytotoxic and/or helper T lymphocytes 
were located on non-structural and/or latency associated proteins. In acute IM 
patients (approximately 40%), a considerable proportion of HLA B8 restricted CTL 
reactivity is directed against a single peptide (RAKFKQLL) of the trans-activator 
protein BZLF1/Zta/ZEBRA [10].
It must be noted that natural killer cells and anti-EBV cytotoxic T lymphocytes 
(CTLs) are the main players in the immune response that effectively controls infec-
tion [12]. The primary role of anti-EBV CTLs would be to control the proliferation 
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of latently infected B cells. EBV has the feature of implementing various latency 
and lytic transcription programs, suggesting that it assumes distinct antigenic 
states within infected individuals (Table 3) [7, 10]. Yet, despite the wide variety of 
antigens that predominate throughout the EBV life cycle, EBV vaccine candidates 
have traditionally only focused on a limited number of EBV antigens. For a sum-
mary on these vaccine candidates see a review by Cohen [13]. Thus, the EBV vac-
cines designed so far fall into two categories: those preventing any kind of infection 
(including prophylaxis of EBV-associated malignancies) and those designed for 
therapeutic purposes (to be used in subjects already infected) [13].
3. A second challenge: the lack of a true animal model
EBV is highly species-specific and only infects humans and primates. Initial 
studies of EBV vaccines used cottontop tamarins (white-crested), a now endangered 
species [14]. This model has several drawbacks including the very high doses of 
EBV in the challenge inoculum required to cause tumors, a non-physiologic route of 
infection (intraperitoneal injection of virus), and the fact that EBV is not a natural 
pathogen in these animals. Moreover, EBV does not establish a latent infection in the 
B cells of these monkeys which is the case with humans. EBV vaccine studies have 
also been performed in common marmosets and EBV gp350 can protect against the 
parenteral challenge of these animals [15]. The use of an animal virus such as Rhesus 
lymphocryptovirus (LCV) is also a useful model for vaccination studies [16] as it 
is close to EBV and reproduces the majority of EBV symptoms in its natural host 
(the Rhesus macaque). Today, the humanized mouse model looks promising, as it is 
possible to recreate different pathologies associated with EBV [17–19]. However, the 
absence of infection in the epithelial cells of the animal does not allow the reconsti-
tution of all the pathologies associated with EBV in humans. Two types of vaccines 
are currently being studied to control EBV: A prophylactic vaccine that aims to 
neutralize the virus to block infection and a therapeutic vaccine that aims to induce 
or improve the anti-EBV cellular response in some patients.
4. The prophylactic vaccines
In designing a prophylactic vaccine against a virus, induction of a neutralizing 
antibody response is generally sought. Multiple alternative vaccine candidates 
include targeting EBV-based glycoproteins, EBV lytic proteins, and EBV latent 
proteins (Figure 1).
4.1 Which antigens are used?
The glycoproteins of the viral envelope are therefore the preferred targets. EBV 
carries several glycoproteins (gp350, gB, gH, gL, gp42, gM, gN, BMRF2, BDLF2, 
BDLF3, BILF2, BILF1, BARF1) [20] on its surface. To date, the greatest strides 
towards developing an EBV-based vaccine have been made by targeting gp350. This 
type I glycoprotein is crucial for EBV’s ability to enter the host B cells by binding 
their CD21 or CD35 receptor. It is the most abundant glycoprotein on the surface of 
virions and the most expressed by cells infected with EBV. In addition, gp350 is the 
major target of antibodies capable of neutralizing infection of B cells [20]; it is also 
an important antigen and target recognized by cellular immunity [10]. Other EBV 
glycoproteins such as (i) gH/gL (member of the fusion complex); (ii) gp42 (deter-
mines the cellular tropism of EBV); and (iii) gB (a class III type of viral fusion protein 
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also essential for maturation and egress) have also been tested in various vaccine trials 
[7]. They are also able to induce the expression of neutralizing antibodies. They do, 
however, appear to be less effective than those directed against gp350 (see Table 3).
For the various reasons cited above, most vaccination trials have been car-
ried out using recombinant gp350 [6, 7, 13]. The production of viral-like particles 
(VLPs) which do not contain a genome and in which several viral proteins involved 
in cell transformation have been inactivated or deleted has also been described. 
The vaccination of mice with these VLPs induces the production of neutralizing 
antibodies and cellular immune response [7, 21]. Although, while this approach is 
promising, given the oncogenic properties of EBV, the acceptability of this type of 
vaccine for use in human health remains uncertain.
4.2 The clinical trials
Several vaccines have been evaluated to prevent infection and protect against 
the symptomatic episode of primary infection (IM) [13]. The first vaccine trial 
in humans was undertaken by Gu and colleagues [22] using a live recombinant 
vaccinia virus/major EBV envelope antigen BNLF-1 MA (gp220–340) construct. 
The authors showed that for the first time it was possible to protect against and/or 
delay EBV infection by the natural route. The most advanced study of the safety, 
immunogenicity and efficacy of an EBV vaccine has been reported by Sokal and 
colleagues [23]. In their study (NCT00430534), a group of 181 EBV seronegative 
volunteers between the ages of 16 and 25 received three doses of a recombinant 
gp350 vaccine or placebo. The authors claimed the vaccine had demonstrable 
efficacy (mean efficacy rate, 78.0% [95% confidence interval: 1.0–96%]) and that 
there were no concerns regarding safety or immunogenicity. Over an observation 
period of 18 months, the vaccination of the young adults with recombinant gp350 
reduced the risk of developing an IM of 10% in controls to only 2% in vaccinated 
people. However, despite the production of neutralizing antibodies, vaccination 
does not appear to prevent infection. This result suggests that the vaccine used may 
reduce the risk of associated pathogenesis without necessarily preventing infection. 
The same type of vaccine that was given to patients not infected with EBV, and who 
were waiting for a kidney transplant, did not seem to give satisfactory results (only 
30% produced neutralizing antibodies). The unsatisfactory results were probably 
Figure 1. 
An EBV vaccination strategy: Whatever EBV vaccine candidates, they will not block infection. However, they 
could prevent the onset of the symptoms of infection and reduce the risk of developing EBV-associated tumors or 
EBV-associated pathology (i.e. MS).
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because patients in this study suffered from both an immunosuppressed state and 
renal impairment [24].
Alternative EBV vaccines such as, a virus-like particle EBV vaccine [21] and a 
CD8+ T-cell peptide epitope-based vaccine [25]. have been evaluated in Phase 1 
clinical trials. To date, several phases I and phase II clinical trials have been carried 
out and have yielded rather encouraging results [7, 26].
In 10% of cases, IM is associated with quite severe symptoms (such as prolonged 
asthenia, risk of Hodgkin’s lymphoma) [27–29] and in the most serious cases with 
neurological involvement (1%) [3, 30]. Given the vast variability in these results 
and the long period from an EBV infection to the onset of MS, such EBV vaccine tri-
als in MS populations are not feasible. With a 30 times greater rate of MS occurrence 
in first-degree relatives when compared to unrelated populations, such intervention 
may potentially decrease the overall MS incidence [31]. This explains the increasing 
interest in developing EBV vaccines to prevent MS. Given the association of IM with 
MS, there is a strong possibility of reducing this childhood infection by eradicating 
MS. [32]. So far, however, there is no licensed EBV vaccine and to make progress 
regarding its development, a greater understanding of the association of EBV with 
MS is required [33]. Recent advances have pointed to the use of EBV vaccines to 
control MS. Indeed, both asymptomatic EBV infection and IM have also been asso-
ciated with an increase in MS susceptibility [33, 34]. The imminent increase in MS 
risk following an EBV seroconversion has been expertly shown through a study that 
utilized serial blood samples derived from more than 8 million active-duty military 
personnel [35].
Other potential targets for vaccine development include immediate and early 
EBV proteins that are expressed during the first steps of the lytic cycle. Both Zta 
and Rta immediate proteins (encoded by BZLF1 and BRLF1, respectively) are easily 
recognizable due to an uninhibited CD8+ T-cell response [36]. On the other hand, 
the early lytic proteins BMLF1 and BMRF1 can be detected by CD4+ T cells as 
early as the first day of EBV infection [37]. Studies have examined the utility of the 
BZLF1 vaccine in mice models of EBV-induced post-transplant lymphoprolifera-
tive disorder and shown successful T-cell immunity induction towards the infected 
tumor cells [38]. Lastly, recent evidence also shows that the latent proteins (EBNA) 
can be recognized by CD8+ and CD4+ T cells and prevent further expansion of 
EBV-infected B cells [37]. As we now understand the importance of B cells in the 
MS pathophysiology, we can conclude that this type of vaccine intervention would 
potentially exert a therapeutic outcome [39]. In contrast, an effective EBV vaccine 
that could prevent the 200,000 new EBV-associated malignancies occurring glob-
ally each year is not currently available despite the considerable efforts expended in 
developing EBV gp350 vaccines [6]. Very recently, in 2020, the Moderna Company 
(Cambridge, MA, USA) carried an innovative mRNA-based EBV vaccine (mRNA-
1189) (https://investors.modernatx.com/static-files/834b6509-553f-4ee5-84e0-
c198bbb850f0). Preclinical data demonstrated the ability to induce antibodies 
against EBV antigens: Naïve Balb/c mice were given two doses of a vaccine against 
EBV antigens in combination approximately 4 weeks apart. Antibody titers against 
viral proteins involved in epithelial cell entry (gH/gL and gB) or B cell entry 
(gp350, gH/gL and gB) (Table 3) were measured in peripheral blood at day 57. 
Their last results demonstrated high levels of anti-EBV neutralizing antibodies, and 
at levels significantly higher than those observed in naturally-infected human sera.
4.3 Major drawbacks of the prophylactic EBV vaccine strategies
Contrary to Epstein’s initial idea, an EBV vaccination does not block infection. 
However, it could prevent the onset of the symptoms of infection and reduce the 
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risk of developing EBV-associated tumors. Moreover, the correlates of protection 
against EBV infection and diseases (in animal models and humans) are not clearly 
defined, so it is hard to reliably predict the ideal EBV vaccine targets and whether 
humoral immunity or cellular immunity or both should be involved. Currently, the 
definitions of a goal for an EBV vaccine and criteria for licensure to prevent diseases 
rather than infections are not clear.
5. The therapeutic vaccines
In the case of a therapeutic vaccine, the induction of cellular immunity against 
EBV in patients suffering from certain pathologies (NPC, HD, etc.) is the main 
objective. One of the difficulties of this approach is that the number of viral pro-
teins expressed in cancer cells varies according to the pathology concerned. The 
EBNA-1 protein is the only viral protein expressed in all cases of EBV-associated 
cancers. It is also one of the main targets of CD4 T cells along with the membrane 
proteins LMP1 and LMP2 which are also good targets for CD8 T cells. This makes 
this type of approach possible. The relevance of designing a therapeutic anti-EBV 
vaccine is based on clinical observations from tests of infusions of EBV-specific 
T lymphocytes (CTLs directed against the viral proteins LMP1 and LMP2). In 
patients with Hodgkin’s lymphoma, non-Hodgkin’s lymphoma or nasopharyngeal 
carcinoma (NPC), the results of the first studies are encouraging - this specific EBV 
cell therapy can markedly improve the survival of some of these patients [7, 40–42]. 
Therefore, a vaccine that induces T-cell responses to tumor-expressed EBV latency 
proteins could improve patient survival.
In the context of cure therapy, the adoptive transfer of EBV-specific T cells 
has been therapeutically explored for decades with clinical success [43]. To avoid 
naturally occurring EBV-specific autologous T-cell selection from every patient, the 
transgenic expression of latent and early lytic viral antigen-specific TCRs essen-
tial to redirect T cells and to target the respective tumors has been investigated. 
The latest evidence suggests that not only TCRs against transforming latent EBV 
antigens, but also against early lytic viral gene products, might be protective for 
the control of EBV infection and associated oncogenesis [44]. At the same time, 
these approaches might be more selective and cause less collateral damage rather 
than targeting general B-cell markers with chimeric antigen receptors (CARs). 
Thus, EBV-specific TCR transgenic T cells constitute a brilliant therapeutic strategy 
against EBV-associated malignancies [45]. As an example, recent studies describ-
ing CD8+gp350CAR-T cells showed proof-of-concept preclinical efficacy against 
impending EBV+ lymphoproliferation and lymphomagenesis [46].
6. Uncertainties surrounding EBV vaccines
Despite the very encouraging results obtained in phase II clinical trials, to date, 
no phase III trials have been implemented. The reason why no further development 
of this vaccine has been done is not known. Given the large diversity of pathologies 
associated with EBV, it is unlikely that a single vaccine applicable to all diseases 
associated with EBV can be developed. Vaccination against EBV must take into 
account various factors such as the geographic characteristics of certain pathologies 
(NPC in South-East Asia, endemic Burkitt’s lymphoma (BL) in equatorial Africa), 
the incubation period necessary between infection and development of the disease 
pathology (IM: 4 to 6 weeks, NPC: > 30 years), and the initial age of infection. Such 
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disparity complicates vaccination strategies which would need to be implemented. 
Despite this and depending on the pathology involved, it is still worth consider-
ing further research on an anti-EBV vaccination program. According to a recent 
US study among university students, 37% were EBV negative when they entered 
university, but 3 years later 46% of them had experienced EBV seroconversion. Of 
these, 77% went on to develop an NID. It is interesting to note that IM is the most 
common cause of absenteeism among new recruits to the US military. In developed 
countries, these epidemiological observations support the idea of administering 
a vaccine capable of preventing the disease when administered to children aged 
between 11 and 12 who are EBV negative (in tandem with the administration of a 
vaccine such as a papillomavirus). Such a vaccine would reduce the risk of develop-
ing IM and would also reduce the risk of developing Hodgkin lymphoma [47] or MS 
[30], pathologies which are linked to EBV and which are most likely to be a conse-
quence of the EBV-induced immunological disorder in IM [48].
The value of an EBV vaccination to protect children against BL, especially in 
Africa, is certainly significant. Nevertheless, in this region of the world, infection 
with EBV generally occurs early (50% of children are infected by their 1st year), 
and it is certainly not easy to vaccinate at this stage, especially if three injections 
are required to achieve protective immunity. It is, however, not impossible and has 
been implemented in some countries where children are given vaccinations which 
include hepatitis B in early childhood.
EBV is associated with various lympho-proliferations in immunocompromised 
people, especially following transplantation, or HIV infection. The risk of develop-
ing PTLD is 25 to 30 times higher in an EBV-negative person before the transplant 
than in a person who was HIV-positive. Prophylactic vaccination against EBV 
would not only reduce the risks associated with the primary infection but could also 
decrease the risk of developing PTLD during transplantation; the latter hypothesis 
has not yet been evaluated. Regarding NPC and gastric carcinoma, only retrospec-
tive studies after prophylactic vaccination could reveal its efficacy. It would then 
be necessary to demonstrate the direct effects of a prophylactic vaccine aimed at 
preventing these pathologies which develop more than 30 years after infection. 
Nevertheless, this has already been achieved with the hepatitis B vaccination 
program which is performed in children and protects against the development of 
liver cancer 15 to 20 years later.
7. The EBV diagnostic tests as a predictor of diseases
Taking into account the above-mentioned points, it is undoubtedly time to turn 
to predictive tests to prevent the appearance of the first signs of pathology both in 
the context of cancers (lymphomas) and in the context of chronic pathologies.
7.1 What about conventional EBV diagnostic tests?
EBV serology was for a long time the only technique used for diagnosis. In 
immunocompromised patients, serological tests (looking for IgG and IgM antibodies 
directed against two types of viral antigens - capsid and EBNAs) are used to identify 
the immune status to EBV in the donor/recipient (before transplantation) and in 
HIV patients. They are not used for primary or hereditary immunodeficiencies. 
With regards to EBV serology, the practice is relatively homogeneous with an assay 
combining anti-VCA IgG, anti-VCA IgM and anti-EBNA IgG. The combined use of 
these three markers is sufficient for most diagnoses, making it possible to distinguish 
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the primary infection (±, +, −) from an old infection (+, −, +). Depending on the 
manufacturers of diagnostic kits, the detection technique (ELISA or immunofluo-
rescence) and the nature of the antigen targets (recombinant proteins, infected cells, 
peptides, etc.) of these antibodies may vary, but most of the techniques used are 
validated for their diagnostic capacities by expert medical virology laboratories at 
the time of marketing.
The ability to accurately determine viral load (DNA PCR) for HHV infections 
post-transplantation [4] has become a mainstay for diagnostics especially in the 
context of the beta and gamma herpesviruses. Most approaches use real-time 
quantitative PCR-based assays [49]. PTLD (classified into six categories by WHO) 
has become a deleterious complication of both solid-organ and hematopoietic 
stem-cell transplantation. Data from large transplantation registries have shown 
an increased incidence of PTLD and significant associations with morbidity and 
mortality [50, 51]. EBV viral load monitoring is now routine and high viral loads 
are often associated with concurrent PTLD. But data linking EBV kinetics to the 
risk of developing PTLD remain controversial. Measurement of EBV viral load 
by quantitative PCR is an essential test in the follow-up of children with solid 
organ transplants. It is used: (i) to prevent the development of PTLD (by adapt-
ing immunosuppression and/or by initiating pre-emptive treatment); (ii) in the 
monitoring of pre-emptive treatment; and (iii) in the follow-up of the curative 
treatment of PTLD.
It should be emphasized that there is a difference between patients who have 
had solid organ allografting and HSCT patients [50]. Immunosuppressive treat-
ments in solid organ allograft recipients are modest compared to HSCT recipients 
who receive more severe immunosuppressive treatment. Correlations between 
higher EBV loads and the development of PTLD are seen in solid organ allograft 
recipients, but these correlations do not indicate high positive and negative 
predictive values [52]. There is considerable overlap between the EBV loads in 
patients with PTLD and those in patients without PTLD. Furthermore, solid 
organ allograft recipients receive lifelong immunosuppression so that there is 
a long-term risk of EBV-PTLD. Therefore, routine surveillance for EBV-DNA 
by quantitative PCR is not recommended in adult recipients [53]. Solid-organ 
allograft recipients also sometimes carry chronic high EBV loads without symp-
toms consistent with PTLD [53, 54]. However, the significance of a high EBV 
load in terms of long-term health is unknown. Conversely, in children at high risk 
of primary EBV infection, routine surveillance is beneficial for the preemptive 
identification of patients at high risk of PTLD [53]. Finally, a current article inves-
tigating both the EBV DNA load in whole blood and EBV serology in HIV-infected 
patients with classical Hodgkin concluded that EBV DNA loads at diagnosis were 
not prognostic [55].
Not unlike the situation with CMV, the lack of an international genome standard 
for quantification of EBV in molecular assays makes a comparison of thresholds for 
impending PTLD difficult to interpret [4]. In contrast, EBV infection and in par-
ticular EBV-driven PTLD is a more difficult disease to manage with little evidence 
that antiherpes drugs are effective especially once PTLD is manifest [4]. Anti-CD20 
antibodies (Mabthera®) are not introduced until PTLD has been confirmed. In 
contrast, for other types of transplants (intestines, lung, heart, kidneys), anti-CD20 
antibodies can be used earlier and they are part of the pre-emptive treatment. There 
is currently no consensus on the best preemptive strategy because the threshold, 
or kinetics, of preemptive intervention is difficult to define. Typically, a one-log 
increase in viral load is a warning sign. It should be noted that the therapeutic deci-
sion is based on a set of arguments which are virological, clinical (such as tonsillar 
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hypertrophy for example) or biological (for example LDH, uric acid)), because the 
EBV viral load is not the only predictive marker of PTLD.
7.2 New biomarkers and therapies exploring the lytic cycle
For decades, many articles have reported the presence of an EBV lytic cycle 
in tumor cells from HL, NPC, in transplant patients, and breast tumors. Clinical 
studies on EBV lytic proteins including ZEBRA in patients with PTLD or HIV-
associated non-Hodgkin lymphoma NHL are mostly related to the role of these 
proteins in neoplastic tissues. Both high EBV copy number and strong BZLF1 
mRNA expression in the peripheral blood lymphocytes (PBL) of patients are sensi-
tive markers of EBV-related PTLD. Soluble ZEBRA concentrations of >100 ng/mL 
detected by an enzyme-linked immunosorbent assay (ELISA) in serum of patients 
after solid organ or hematopoietic stem cell transplant were predictive of PTLD in 
80% of the cases within 3 weeks [56] (for a review see ref. 57). Thus, ZEBRA test-
ing in serum could help identify patients likely to develop severe outcomes during 
the critical post-transplant period and serve as a potential diagnostic/prognostic 
marker for EBV follow-up in immunocompromised patients (Figure 2).
The relevance of the EBV lytic cycle to human pathology prompted researchers 
to target certain lytic proteins with therapeutic aims [57]. As an example, adenovi-
rus vectors expressing BZLF1 or BRLF1 were used to treat EBV-positive tumors [58]. 
On the other hand, the Food and Drug Administration (FDA)-approved lefluno-
mide, which targets EBV replication, was shown to inhibit the earliest step of lytic 
EBV reactivation (BZLF1 and BMRF1 expression) and prevented the development 
of EBV-induced lymphomas in both a humanized mouse model and a xenograft 
model [59]. More recently, duvelisib (a molecule inhibiting the PI3K/AKT signal-
ing pathway, and BCR signaling) was shown to reduce cell growth and expression 
of EBV lytic genes BZLF1 and gp350/220 in EBV-positive cell lines [60]. The 
histone deacetylase (HDAC) and DNA methyltransferase inhibitors are also pos-
sible avenues to suppress the ZEBRA expression and the entire lytic cascade [61]. 
To summarize, efforts should be made to improve the relevance of using ZEBRA 
protein in future EBV vaccine settings [62].
Figure 2. 
ZEBRA as a specific marker measuring early activation of replication of the oncogenic EBV, providing more 
precise monitoring of posttransplant lymphoproliferative disorder development in transplant patients. (from 
Habib et al. [56] with permission) (HSC = hematopoietic stem cells).
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8. Conclusion
The issue of an EBV vaccine is a very actual topics since there is more and more 
evidence for an association between EBV primary infection (IM) and the develop-
ment of multiple sclerosis (MS) and Hodgkin’s lymphoma. Numerous prophylactic 
IM vaccines targeting EBV proteins have been developed. They have shown partial 
success in reducing IM but have failed to prevent EBV infection. Therapeutic vac-
cines against NPCs have had considerable success, but there is a need to improve 
their effectiveness. Increasing vaccine activity in NPC (or gastric carcinoma) might 
be difficult due to a long latency period between primary infection and the develop-
ment of these carcinomas (see Table 4) [63]. The addition of new targets and the 
recent advances in mRNA vaccines may further improve the efficacy of therapeutic 
and prophylactic vaccines against EBV [64].
However, the design of a prophylactic vaccine against EBV poses serious prob-
lems: It is still difficult to find exact correlates of protection and it is still problem-
atic to define the populations intended to receive the vaccine. Immunotherapeutic 
strategies, including CAR T cells, are emerging as new platforms for the treatment 
of tumors associated with EBV [45, 46]. The incorporation of immunotherapeutic 
strategies as first-line treatment may provide better long-term results. It remains 
to be seen how the various immunotherapeutic strategies will be incorporated into 
future therapeutic strategies.
On the other hand, the design of new predictive tests (i.e. ZEBRA-based) 
capable of monitoring the intensity of EBV reactivation and tumor progression, 
could more easily help the physician to monitor the course of pathologies linked to 
Prospects Progress Problems
Prevention of infectious 
mononucleosis
IM was prevented in a phase 
2 study with a subunit gp350 
vaccine [23]
A CD8+ T-cell peptide 
(EBNA3-TT) vaccine was 
immunogenic with a hint of 
efficacy [25]
Duration of protection unknown. Viral 
loads and T-cell-specific responses were 
not evaluated. The ideal age’ which to 





Vaccinia constructs expressing 
EBV glycoprotein (gp 220–340) 
are immunogenic and may 
have reduced incidence of EBV 
infection in Chinese children
CD8+ T-cell peptide vaccine: HLA 
restricted.
The long incubation period from EBV 
infection to the development of NPC 
makes efficacy trials impractical.
Prevention of 
lymphomas
Subunit gp 350 vaccines are safe 
in pediatric renal transplant 
candidates
The vaccine was poorly immunogenic 
probably due to the low dose and weak 
adjuvant; the trial could not assess 
protection from PTLD
Treatment of NPC Vaccinia recombinant vectors 
expressing the tumor-
associated latent or lytic 
viral antigens aresafe and 
immunogenic [41, 42, 58]
Therapeutic efficacy has not yet been 
assessed
Prevention of multiple 
sclerosis
Evidence that a vaccine could 
work: EBV-specific CD8+ T cell 
responses are elevated during 
active MS [39].
The long incubation period from EBV 
infection to MS makes vaccine efficacy 
trials impractical except perhaps in 
first-degree relatives
Table 4. 
Prospects, progress and problems in EBV vaccine development (from Balfour HH [63]).
Please use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
Securing Connection...Acrobat is locking documen loading.com
r
File cannot be found.
13





*Address all correspondence to: emmanuel.drouet@ibs.fr
EBV replication (i.e. lymphomas, MS). Such approaches will easily make it possible 
to initiate pre-emptive antiviral treatments; in addition, these diagnostic tests have 
the advantage of being minimally invasive and inexpensive.
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